KR20140062702A - 예방접종 및 진단 적용에서의 폴리오마 바이러스 jc 펩티드 및 단백질 - Google Patents

예방접종 및 진단 적용에서의 폴리오마 바이러스 jc 펩티드 및 단백질 Download PDF

Info

Publication number
KR20140062702A
KR20140062702A KR1020147004608A KR20147004608A KR20140062702A KR 20140062702 A KR20140062702 A KR 20140062702A KR 1020147004608 A KR1020147004608 A KR 1020147004608A KR 20147004608 A KR20147004608 A KR 20147004608A KR 20140062702 A KR20140062702 A KR 20140062702A
Authority
KR
South Korea
Prior art keywords
protein
jcv
peptide
pml
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147004608A
Other languages
English (en)
Korean (ko)
Inventor
일리야스 옐시크
로란트 마르틴
스벤 쉬플링
미라이아 소스페드라
자라 요우제프
Original Assignee
유니베르시태트 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니베르시태트 취리히 filed Critical 유니베르시태트 취리히
Publication of KR20140062702A publication Critical patent/KR20140062702A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020147004608A 2011-07-22 2012-07-23 예방접종 및 진단 적용에서의 폴리오마 바이러스 jc 펩티드 및 단백질 Withdrawn KR20140062702A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006031A EP2548567A1 (en) 2011-07-22 2011-07-22 Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP11006031.6 2011-07-22
PCT/EP2012/064445 WO2013014134A2 (en) 2011-07-22 2012-07-23 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications

Publications (1)

Publication Number Publication Date
KR20140062702A true KR20140062702A (ko) 2014-05-26

Family

ID=46548481

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147004608A Withdrawn KR20140062702A (ko) 2011-07-22 2012-07-23 예방접종 및 진단 적용에서의 폴리오마 바이러스 jc 펩티드 및 단백질

Country Status (12)

Country Link
US (1) US9738690B2 (cg-RX-API-DMAC7.html)
EP (2) EP2548567A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014520877A (cg-RX-API-DMAC7.html)
KR (1) KR20140062702A (cg-RX-API-DMAC7.html)
CN (1) CN103826653A (cg-RX-API-DMAC7.html)
AU (1) AU2012288955B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014001516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842543A1 (cg-RX-API-DMAC7.html)
EA (1) EA201490322A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198517A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014000776A (cg-RX-API-DMAC7.html)
WO (1) WO2013014134A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065367A1 (en) * 2011-12-12 2015-03-05 Janssen Diagnostics Bvba Polyomavirus peptide sequences
US10300116B2 (en) 2013-06-10 2019-05-28 Ansun Biopharma, Inc. Treatment for BK polyomavirus infection
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
EP2926831A1 (en) * 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
WO2016104046A1 (ja) * 2014-12-22 2016-06-30 日東電工株式会社 透明導電性フィルム
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
CN113278634B (zh) 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) 1995-06-23 2006-04-19 エーザイ株式会社 抗jcウイルス抗体
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE10131145B4 (de) 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 JCウイルスagnoを対象としたPMLの治療
AU2003238008A1 (en) 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
JP2005341864A (ja) 2004-06-02 2005-12-15 Japan Science & Technology Agency Jcウイルスの粒子形成阻害剤
US7468186B2 (en) * 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
US20080057079A1 (en) 2006-08-31 2008-03-06 Baylor Research Institute JC Virus Vaccine
CN100595765C (zh) * 2008-06-30 2010-03-24 腾讯科技(深圳)有限公司 基于媒体播放器的关键词内容发布方法及系统
AU2010210979B2 (en) * 2009-02-05 2015-12-10 Biogen Ma Inc. Methods for the detection of JC polyoma virus
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
EP2226392A1 (en) * 2009-03-03 2010-09-08 Assistance Publique - Hôpitaux de Paris Method for detecting JCV infection
WO2011124652A1 (en) * 2010-04-08 2011-10-13 Fondazione Centro San Raffaele Del Monte Tabor Immunodominant peptide of polyomavirus jc and uses thereof

Also Published As

Publication number Publication date
US9738690B2 (en) 2017-08-22
MX2014000776A (es) 2014-11-26
CN103826653A (zh) 2014-05-28
CA2842543A1 (en) 2013-01-31
AU2012288955B2 (en) 2017-06-08
WO2013014134A2 (en) 2013-01-31
WO2013014134A3 (en) 2013-05-02
JP2014520877A (ja) 2014-08-25
BR112014001516A2 (pt) 2017-02-14
AU2012288955A1 (en) 2014-02-20
EP2548567A1 (en) 2013-01-23
HK1198517A1 (en) 2015-05-15
EP2734218A2 (en) 2014-05-28
NZ620196A (en) 2016-10-28
US20140356320A1 (en) 2014-12-04
EA201490322A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
CN110088623B (zh) 选择用于治疗免疫病症的高效干细胞的方法
US9738690B2 (en) Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
Aly et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome
AU2021263607A1 (en) Treatment and prevention of cancer using virus-specific immune cells expressing chimeric antigen receptors
JP2015529676A (ja) 作用物質および方法
US8629108B2 (en) Rheumatoid arthritis T cell vaccine
JP2023525084A (ja) 多発性硬化症の処置のためのペプチド及び方法
WO2021232048A1 (en) Sars-cov-2-specific t cells
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
KR20190140912A (ko) 면역성 조절을 위한 펩티드, 폴리펩티드 또는 세포의 제조 방법
US12168046B2 (en) Mycobacterial antigen compositions and methods of use
US20220409716A1 (en) T-cell compositions and methods of making and using the same
JP2023527205A (ja) 改良されたワクチン製剤
NZ620196B2 (en) Polyoma virus jc peptides and proteins in vaccination and diagnostic applications
Gupta Inhibiting Auto-Antigen Presentation on MHC Class-II by Small Molecules in Sjogren’s Syndrome
Kuo Association of local immune suppression in skin with HPV-induced epithelial hyperplasia
Smith IL-23 Receptor Expression and Effects of Signaling on T Cell Encephalitogenicity
Naive De Novo Recruitment of Antigen-Experienced
Policano Non heritable risk factors for multiple sclerosis: epstein barr virus and elements influencing intestinal permeability
Williams et al. BSI 2010

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid